Mitiglinide in Combination With Metformin vs. Metformin Alone in Patients With Type 2 Diabetes Mellitus

This study has been completed.
Sponsor:
Information provided by:
Elixir Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00519142
First received: August 20, 2007
Last updated: September 16, 2009
Last verified: September 2009
  Purpose

The primary objective of this study is to demonstrate whether mitiglinide administered in combination with metformin is more effective than metformin alone in patients with Type 2 diabetes mellitus (T2DM) whose blood sugar is not well controlled taking metformin alone. This is a 24 week study which measures improvement in blood sugar after of treatment.


Condition Intervention Phase
Diabetes Mellitus, Type 2
Drug: placebo for mitiglinide
Drug: mitiglinide
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Rapid Onset and Short Duration Insulin Secretogogue, Mitiglinide, in Combination With Metformin Versus Metformin Alone in Patients With Type 2 Diabetes Mellitus: A Randomized, Double-blind, Placebo-controlled Trial for 6 Months

Resource links provided by NLM:


Further study details as provided by Elixir Pharmaceuticals:

Primary Outcome Measures:
  • change from baseline in HbA1c [ Time Frame: after 24 weeks of treatment ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • change from baseline in 2-hour post-prandial glucose [ Time Frame: after 24 weeks of treatment ] [ Designated as safety issue: No ]
  • change from baseline in fasting plasma glucose [ Time Frame: after 24 weeks of treatment ] [ Designated as safety issue: No ]

Enrollment: 367
Study Start Date: August 2007
Study Completion Date: October 2008
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: 1
metformin + placebo for mitiglinide
Drug: placebo for mitiglinide
three times a day with meals
Experimental: 2
metformin + mitiglinide three times a day with meals
Drug: mitiglinide
three times a day with meals
Experimental: 3
metformin + mitiglinide two times a day with morning and evening meal, placebo for mitiglinide with midday meal
Drug: mitiglinide
two times a day with meals

Detailed Description:

This is a randomized, double-blind, placebo-controlled, parallel group study designed to evaluate the efficacy and safety of mitiglinide in combination with metformin in patients with T2DM who are less than adequately controlled on metformin alone. Patients who are receiving metformin alone for T2DM will be randomized equally into one of three treatment groups.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • type 2 diabetes diagnosed for at least 6 months
  • stable metformin usage for at least 4 months
  • HbA1c 7.5% - 10.5% inclusive
  • no severe diabetic complications

Exclusion Criteria:

  • chronic insulin use
  • use of oral diabetic agent within 12 weeks
  • acute or chronic conditions, excluding diabetes, that could compromise end point evaluation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00519142

  Hide Study Locations
Locations
United States, Arizona
Elixir Study Site
Glendale, Arizona, United States
United States, California
Elixir Study Site
Greenbrae, California, United States
Elixir Study Site
La Jolla, California, United States
Elixir Study Site
Los Angeles, California, United States
Elixir Study Site
Los Gatos, California, United States
Elixir Study Site(s)
Oakland Area, California, United States
Elixir Study Site
Orange, California, United States
Elixir Study Site
West Hills, California, United States, 91307
Elixir Study Site
Westlake Village, California, United States
United States, Colorado
Elixir Study Site
Pueblo, Colorado, United States
United States, District of Columbia
Elixir Study Site(s)
Washington, District of Columbia, United States
United States, Florida
Elixir Study Site
Chiefland, Florida, United States, 32626
Elixir Study Site
Coral Gables, Florida, United States
Elixir Study Site
Kissimmee, Florida, United States
Elixir Study Site(s)
Miami, Florida, United States
Elixir Study Site
St. Cloud, Florida, United States
Elixir Study Site
Winter Park, Florida, United States
United States, Georgia
Elixir Study Site
Atlanta, Georgia, United States, 30080
Elixir Study Site
Austell, Georgia, United States
Elixir Study Site
Perry, Georgia, United States
United States, Illinois
Elixir Study Site(s)
Chicago, Illinois, United States
United States, Kansas
Elixir Study Site
Wichita, Kansas, United States
United States, Missouri
Elixir Study Site
Kansas City, Missouri, United States, 64132
Elixir Study Site
St Louis, Missouri, United States, 63110
United States, Nevada
Elixir Study Site
Las Vegas, Nevada, United States
United States, New Jersey
Elixir Study Site
Hamilton, New Jersey, United States
Elixir Study Site
Hillsborough, New Jersey, United States
Elixir Study Site
Sewell, New Jersey, United States
United States, New York
Elixir Study Site(s)
New York, New York, United States
United States, North Carolina
Elixir Study Site
Mooresville, North Carolina, United States
Elixir Study Site
Morehead City, North Carolina, United States
United States, Ohio
Elixir Study Site
Akron, Ohio, United States
Elixir Study Site
Cincinnati, Ohio, United States
Elixir Study Site
Gallipolis, Ohio, United States
Elixir Study Site
Kettering, Ohio, United States
United States, Oregon
Elixir Study Site
Medford, Oregon, United States
United States, Pennsylvania
Elixir Study Site
Harleysville, Pennsylvania, United States
Elixir Study Site
Levittown, Pennsylvania, United States
Elixir Study Site
Uniontown, Pennsylvania, United States
United States, South Carolina
Elixir Study Site
Columbia, South Carolina, United States
Elixir Study Site
Simpsonville, South Carolina, United States
United States, Tennessee
Elixir Study Site
Memphis, Tennessee, United States
Elixir Study Site
Tullahoma, Tennessee, United States
United States, Texas
Elixir Study Site(s)
Dallas, Texas, United States
Elixir Study Site
El Paso, Texas, United States
Elixir Study Site(s)
Fort Worth, Texas, United States
Elixir Study Site(s)
Houston, Texas, United States
Elixir Study Site
Humble, Texas, United States
Elixir Study Site
Midland, Texas, United States
Elixir Study Site
N. Richland Hills, Texas, United States
Elixir Study Site
New Braunfels, Texas, United States
Elixir Study Site
Pearland, Texas, United States
Elixir Study Site
Plano, Texas, United States, 75074
Elixir Study Site(s)
San Antonio, Texas, United States
Elixir Study Site
Temple, Texas, United States
United States, Virginia
Elixir Study Site
Norfolk, Virginia, United States
United States, Washington
Elixir Study Site
Federal Way, Washington, United States
Puerto Rico
Elixir Study Site
Carolina, Puerto Rico, 00983
Elixir Study Site
Fajardo, Puerto Rico, 00738
Elixir Study Site(s)
Ponce, Puerto Rico
Elixir Study Site(s)
San Juan, Puerto Rico
Sponsors and Collaborators
Elixir Pharmaceuticals
Investigators
Study Director: Paul Martha, MD Elixir Pharmaceuticals
  More Information

No publications provided

Responsible Party: Paul Martha, Chief Medical Officer, Elixir Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00519142     History of Changes
Other Study ID Numbers: EX-1510-CT-003
Study First Received: August 20, 2007
Last Updated: September 16, 2009
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Metformin
Mitiglinide
Hypoglycemic Agents
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on October 22, 2014